Adult lifetime cost of hemophilia B management in the US: payer and societal perspectives from a decision analytic model
Li N, Sawyer E, Maruszczyk K, Guzauskas G, Slomka M, Burke T, Martin A, O’Hara J, Stevenson M, Recht M. Adult lifetime cost of hemophilia B management in the US: payer and societal perspectives from a decision analytic model. Journal Of Medical Economics 2021, 24: 363-372. PMID: 33591884, DOI: 10.1080/13696998.2021.1891088.Peer-Reviewed Original ResearchConceptsStandard half-lifeExtended half-lifeSevere HBFactor IXHemophilia BAssociated health resource utilizationUS third-party payerFactor IX prophylaxisBleeding-related complicationsLifetime costsFixed treatmentStandard of careChronic joint damageTreatment costsSocietal perspectiveHealth resource utilizationHalf-lifeDecision-analytic modelClotting factor IXBleeding eventsTreatment paradigmTreatment optionsCongenital disorderProphylaxisLifetime horizon
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply